Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment
- 1 January 2008
- journal article
- letter
- Published by Informa UK Limited in Scandinavian Journal of Rheumatology
- Vol. 37 (5), 399-400
- https://doi.org/10.1080/03009740802004966
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature reviewScandinavian Journal of Rheumatology, 2007
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialAnnals Of The Rheumatic Diseases, 2005
- Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Arthritis & Rheumatism, 2005
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis & Rheumatism, 2004
- Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialThe Lancet, 2000